Amsterdam Cardiovascular Sciences

Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition

Chen, S., Overberg, K., Ghouse, Z., Hollmann, M. W., Weber, N. C., Coronel, R. & Zuurbier, C. J., 1 May 2024, In: Biomedicine and Pharmacotherapy. 174, 116477.

Research output: Contribution to journal › Article › Academic › peer-review

Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2

Chen, S., Wang, Q., Bakker, D., Hu, X., Zhang, L., van der Made, I., Tebbens, A. M., Kovácsházi, C., Giricz, Z., Brenner, G. B. B., Ferdinandy, P., Schaart, G., Gemmink, A., Hesselink, M. K. C., Rivaud, M. R., Pieper, M. P., Hollmann, M. W., Weber, N. C., Balligand, J-L., Creemers, E. E., & 2 othersCoronel, R. & Zuurbier, C. J., 2024, (E-pub ahead of print) In: Basic Research in Cardiology.

Research output: Contribution to journal › Article › Academic › peer-review